Literature DB >> 21102630

Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.

Sanjay Kaul1, George A Diamond.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21102630     DOI： 10.1038/nrcardio.2010.160

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  8 in total

1.  Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Authors:  George A Diamond; Leon Bax; Sanjay Kaul
Journal:  Ann Intern Med       Date:  2007-08-06       Impact factor: 25.391

2.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Authors:  David J Graham; Rita Ouellet-Hellstrom; Thomas E MaCurdy; Farzana Ali; Christopher Sholley; Christopher Worrall; Jeffrey A Kelman
Journal:  JAMA       Date:  2010-06-28       Impact factor: 56.272

Review 3.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  Arch Intern Med       Date:  2010-07-26

4.  Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.

Authors:  Darren K McGuire; Shuaib M Abdullah; Raphael See; Peter G Snell; Jonathan McGavock; Lidia S Szczepaniak; Colby R Ayers; Mark H Drazner; Amit Khera; James A de Lemos
Journal:  Eur Heart J       Date:  2010-07-02       Impact factor: 29.983

5.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

6.  A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

Authors:  Henry J Dargie; Per R Hildebrandt; Günter A J Riegger; John J V McMurray; Stephen O McMorn; Jeremy N Roberts; Andrew Zambanini; John P H Wilding
Journal:  J Am Coll Cardiol       Date:  2007-04-06       Impact factor: 24.094

7.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.

Authors:  Jan O Friedrich; Neill K J Adhikari; Joseph Beyene
Journal:  BMC Med Res Methodol       Date:  2007-01-23       Impact factor: 4.615

8.  Simpson's paradox visualized: the example of the rosiglitazone meta-analysis.

Authors:  Gerta Rücker; Martin Schumacher
Journal:  BMC Med Res Methodol       Date:  2008-05-30       Impact factor: 4.615
  8 in total
  2 in total

1.  Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis.

Authors:  Shanmugam Muruganandan; Sebastian D Parlee; Jillian L Rourke; Matthew C Ernst; Kerry B Goralski; Christopher J Sinal
Journal:  J Biol Chem       Date:  2011-05-14       Impact factor: 5.157

2.  Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Authors:  A Szebeni; N Szentandrássy; P Pacher; J Simkó; P P Nánási; V Kecskeméti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.